Journal of Gynecologic Oncology

Korean Society of Gynecologic Oncology (대한부인종양학회)
권호 표지
DOI QR코드

DOI QR Code

Checkpoint-inhibition in ovarian cancer: rising star or just a dream?

  • Pietzner, Klaus (Department of Gynecology, European Competence Center for Ovarian Cancer (EKZE), Charite-University Medicine of Berlin, Campus Virchow Klinikum) ;
  • Nasser, Sara (Department of Gynecology, European Competence Center for Ovarian Cancer (EKZE), Charite-University Medicine of Berlin, Campus Virchow Klinikum) ;
  • Alavi, Sara (Department of Gynecology, European Competence Center for Ovarian Cancer (EKZE), Charite-University Medicine of Berlin, Campus Virchow Klinikum) ;
  • Darb-Esfahani, Silvia (Department of Pathology, Charite-University Medicine of Berlin, Campus Mitte) ;
  • Passler, Mona (Department of Gynecology, European Competence Center for Ovarian Cancer (EKZE), Charite-University Medicine of Berlin, Campus Virchow Klinikum) ;
  • Muallem, Mustafa Zelal (Department of Gynecology, European Competence Center for Ovarian Cancer (EKZE), Charite-University Medicine of Berlin, Campus Virchow Klinikum) ;
  • Sehouli, Jalid (Department of Gynecology, European Competence Center for Ovarian Cancer (EKZE), Charite-University Medicine of Berlin, Campus Virchow Klinikum)
  • Received : 2018.07.25
  • Accepted : 2018.07.25
  • Published : 2018.11.10
⟨ Previous Next ⟩

Abstract

The introduction of checkpoint inhibitors revolutionized immuno-oncology. The efficacy of traditional immunotherapeutics, like vaccines and immunostimulants was very limited due to persistent immune-escape strategies of cancer cells. Checkpoint inhibitors target these escape mechanisms and re-direct the immune system to anti-tumor toxicity. Phenomenal results have been reported in entities like melanoma, where no other therapy was able to demonstrate survival benefit, before the introduction of immunotherapeutics. The first experience in ovarian cancer (OC) was reported for nivolumab, a fully human anti-programmed cell death protein 1 (PD1) antibody, in 2015. While the data are extraordinary for a mono-immunotherapeutic agent and very promising, they do not match up to the revolutionary results in entities like melanoma. The key to exceptional treatment response in OC, could be the identification of the most immunogenic patients. We hypothyse that BRCA mutation could be a predictor of improved response in OC. The underlying DNA-repair-deficiancy should result in increased immunogenicity because of higher mutational load and more neoantigen presentation. This hypothesis was not tested to date and should be subject to future trials. The present article gives an overview of the immunologic background of checkpoint inhibition (CI). It presents current data on nivolumab and other checkpoint-inhibitors in solid tumors and OC specifically and depicts important topics in the management of this novel substance group, such as side effect control, diagnostic PD-1/programmed cell death-ligand 1 (PD-L1) expression assessment and management of pseudoprogression.

Keywords

References

  1. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 2015;33:4015-22. https://doi.org/10.1200/JCO.2015.62.3397
  2. Karre K. NK cells, MHC class I molecules and the missing self. Scand J Immunol 2002;55:221-8. https://doi.org/10.1046/j.1365-3083.2002.01053.x
  3. Topfer K, Kempe S, Muller N, Schmitz M, Bachmann M, Cartellieri M, et al. Tumor evasion from T cell surveillance. J Biomed Biotechnol 2011;2011:918471.
  4. Nurieva R, Wang J, Sahoo A. T-cell tolerance in cancer. Immunotherapy 2013;5:513-31. https://doi.org/10.2217/imt.13.33
  5. Wu P, Wu D, Li L, Chai Y, Huang J. PD-L1 and survival in solid tumors: a meta-analysis. PLoS One 2015;10:e0131403. https://doi.org/10.1371/journal.pone.0131403
  6. Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget 2016;7:1486-99.
  7. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28. https://doi.org/10.1056/NEJMoa1501824
  8. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515:558-62. https://doi.org/10.1038/nature13904
  9. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7. https://doi.org/10.1038/nature14011
  10. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8. https://doi.org/10.1126/science.aaa1348
  11. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-20. https://doi.org/10.1056/NEJMoa1500596
  12. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71. https://doi.org/10.1038/nature13954
  13. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-30. https://doi.org/10.1200/JCO.2013.53.0105
  14. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005;11:6422-30. https://doi.org/10.1158/1078-0432.CCR-05-0508
  15. Varga A, Piha-Paul SA, Ott PA, Mehnert JM, Berton-Rigaud D, Johnson EA, et al. Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: interim results from a phase Ib study. J Clin Oncol 2015;33:abstr 5510.
  16. Infante JR, Braiteh F, Emens LA, Balmanoukian AS, Oaknin A, Wang Y, et al. 871P. Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC). Ann Oncol 2016;27:vi296-312.
  17. Lee JM, Dos Santos Zimmer A, Lipkowitz S, Annumziata CM, Ho TW, Chiou VL, et al. Phase I study of the PD-L1 inhibitor, durvalumab (MEDI4736; D) in combination with a PARP inhibitor, olaparib (O) or a VEGFR inhibitor, cediranib (C) in women's cancers (NCT02484404). J Clin Oncol 2016;34:abstr 3015.
  18. Disis ML, Patel MR, Pant S, Hamilton EP, Lockhart AC, Kelly K. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: safety and clinical activity. J Clin Oncol 2016;34:abstr 5533.
  19. Konstantinopoulos PA, Waggoner SE, Vidal GA, Mita MM, Fleming GF, Holloway RW, et al. TOPACIO/Keynote-162 (NCT02657889): a phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC) - results from ROC cohort. J Clin Oncol. Forthcoming 2018.
  20. Oldenburg J, Normann M, Turzer M, Solheim O, Diep LM, Gajdzik B, et al. PD-1 inhibitor treatment of platinum-resistant epithelial ovarian cancer. J Clin Oncol. Forthcoming 2018.
  21. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47. https://doi.org/10.1016/j.ejca.2008.10.026
  22. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 2015;33:3541-3. https://doi.org/10.1200/JCO.2015.61.6870
  23. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20. https://doi.org/10.1158/1078-0432.CCR-09-1624
  24. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15:852-61. https://doi.org/10.1016/S1470-2045(14)70228-1
  25. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104:2807-16. https://doi.org/10.1002/cncr.21536

Cited by

  1. Immunotherapies based on PD‐1/PD‐L1 pathway inhibitors in ovarian cancer treatment vol.195, pp.3, 2018, https://doi.org/10.1111/cei.13255
  2. Pseudo- or real progression? An ovarian cancer patient under nivolumab: A case report vol.10, pp.7, 2018, https://doi.org/10.5306/wjco.v10.i7.247
  3. SELECTED MECHANISMS INDUCING RESISTANCE TO IMMUNOTHERAPY IN PATIENTS WITH OVARIAN CANCER vol.72, pp.7, 2018, https://doi.org/10.36740/wlek201907129
  4. Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers vol.20, pp.10, 2018, https://doi.org/10.1007/s11864-019-0676-8
  5. Immuntherapie beim Ovarialkarzinom vol.53, pp.4, 2018, https://doi.org/10.1007/s00129-020-04579-2
  6. Harnessing natural killer cells for the treatment of ovarian cancer vol.157, pp.3, 2018, https://doi.org/10.1016/j.ygyno.2020.03.020
  7. Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade vol.69, pp.8, 2020, https://doi.org/10.1007/s00262-020-02544-5
  8. Impact of age‐, cancer‐, and treatment‐driven inflammation on T cell function and immunotherapy vol.108, pp.3, 2018, https://doi.org/10.1002/jlb.5mr0520-466r
  9. Association of PD-L1 expression by immunohistochemistry and gene microarray with molecular subtypes of ovarian tumors vol.33, pp.10, 2020, https://doi.org/10.1038/s41379-020-0567-3
  10. Infiltration of T cells promotes the metastasis of ovarian cancer cells via the modulation of metastasis-related genes and PD-L1 expression vol.69, pp.11, 2020, https://doi.org/10.1007/s00262-020-02621-9
  11. Prognostic value of HHLA2 expression in solid tumors : A meta-analysis based on the Chinese population vol.100, pp.30, 2018, https://doi.org/10.1097/md.0000000000026789
  12. The injury response to DNA damage in live tumor cells promotes antitumor immunity vol.14, pp.705, 2021, https://doi.org/10.1126/scisignal.abc4764
  13. Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points vol.13, pp.23, 2021, https://doi.org/10.3390/cancers13236063
  14. Combined lumbar muscle block and perioperative comprehensive patient-controlled intravenous analgesia with butorphanol in gynecological endoscopic surgery vol.9, pp.34, 2018, https://doi.org/10.12998/wjcc.v9.i34.10540